Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases

The transcript covers various topics including the growth prospects of Cosentyx in treating psoriasis and rheumatology, the strategy behind pulling back on price increases in the US, and the impact of policy changes on drug pricing and innovation. It also discusses the spin-off of Alcon as a leading ophthalmology business and the potential effects of global trade conflicts on the pharmacy industry.

How does the speaker view the overall policy environment in the US regarding drug pricing?

What are the unmet needs in healthcare that the speaker refers to?

What is the expected value range for Alcon as mentioned in the discussion?